Wuxi looks to biologics, med devices with expansions in Minnesota, China

By Zachary Brennan

- Last updated on GMT

Related tags: Medical device

Wuxi PharmaTech has completed an expansion of its materials characterization testing facility in St. Paul, Minnesota, as well as its work on a new biologics biosafety testing facility in Suzhou, China.

The 20,000-square-foot laboratory in Minnesota will offer expanded capacity for existing services, like particle identification and extractable/leachable testing, and add a new service—dynamic light scattering for nanoparticle characterization.  These services are required by the FDA for filings of medical devices or biologics. The expansion is designed on a flexible floor plan that allows rapid scale-up of technologies to increase capacities for chemical analysis of medical materials.  

The new expanded laboratory is expected to be operable by the end of June. 

"WuXi is committed to helping medical device and biologics companies bring their products to market faster​," said Ge Li, chairman and CEO of Wuxi.  "This facility and Wuxi's trained staff will better serve our customers' growing need to quantify the chemical safety of materials used in medical devices and biologics​." 

Biosafety Testing Facility in Suzhou

The biosafety testing facility in Suzhou, China, consists of 38,000 square feet of laboratories and support areas in a building adjacent to WuXi's GLP preclinical drug safety facility. Operations will begin after validations are completed this summer. Offerings from the facility will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.

The new services will expand WuXi's biologics services and will mirror the company’s US offerings, which includes biosafety testing services such as viral clearance validation and lot release and stability testing.

In China, the company's services include novel monoclonal antibody discovery, discovery biology, drug screening, cell-line engineering and construction, toxicology, bioanalytical services, assay development, formulation, process development, and cGMP drug-substance and drug-product manufacturing for clinical trials.

"WuXi's expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively​," Li said.  

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more